Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptiv PLCAPTV · Entity 3559 | Director | February 20, 2019 | February 22, 2019 |
| BIOADAPTIVES, INC.BDPT · Entity 1574 | Director | September 01, 2026 | September 03, 2026 |
| CAESARS HOLDINGS, INC.CZR · Entity 11848 | Director · President and CEO | January 30, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptiv PLC
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Dividend Equivalent RightSEC Table II · derivative / convertible security | Direct | 20.363 |
Reported balance
After 2019-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-20 · Grant · Acquired 5.31 · Balance 20.363 F1: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. |
Filing footnotes · ownership attribution and instrument terms
F1: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share.
BIOADAPTIVES, INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 139,640 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Other · Acquired 35,715 · Balance 139,640 F2: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person.
F2: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.
CAESARS HOLDINGS, INC.
Report date January 30, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,125,900 |
Reported balance
After 2019-01-30 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-01-30 · Grant · Acquired 102,624 · Balance 2,125,900 F1: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. |
| Common StockSEC Table I · non-derivative | Direct | 2,085,517 |
Reported balance
After 2019-04-02 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2019-04-02 · Tax withholding · Disposed 40,383 · Balance 2,085,517 F2: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded PSU's that vested on 4/2/2019. F1: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. |
| Common StockSEC Table I · non-derivative | Direct | 2,043,009 |
Reported balance
After 2019-04-02 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2019-04-02 · Tax withholding · Disposed 42,508 · Balance 2,043,009 F3: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded RSU's that vested on 4/2/2019. F1: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. |
| Common StockSEC Table I · non-derivative | Direct | 828,628 |
Reported balance
Holding disclosure · report date 2019-01-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 828,628 F4: Represents shares held in a trust. |
| Common StockSEC Table I · non-derivative | Indirectby daughter | 1,900 |
Reported balance
Holding disclosure · report date 2019-01-30 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,900 F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported.
F2: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded PSU's that vested on 4/2/2019.
F3: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded RSU's that vested on 4/2/2019.
F4: Represents shares held in a trust.
F5: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:05 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 35,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-001451 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,640 Underlying: Common Stock · 3,571,500 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| August 01, 2026 Filed Aug 4, 2026 20:03 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 15,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-001262 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,923 Underlying: Common Stock · 1,515,152 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:10 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-001151 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,771 Underlying: Common Stock · 1,250,000 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:03 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 4,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-26-000750 · e665037_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,271 Underlying: Common Stock · 471,700 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:47 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 4,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-000829 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,554 Underlying: Common Stock · 480,800 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 4,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-000637 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,746 Underlying: Common Stock · 438,600 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:05 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 2,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-000388 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,360 Underlying: Common Stock · 257,800 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:06 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 2,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-000209 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,779 Underlying: Common Stock · 256,500 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:45 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 2,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001640334-26-000020 · form4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,217 Underlying: Common Stock · 228,600 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and theReporting Person. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares ofcommon stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six monthsafter the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting ofstockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 00:04 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-001712 · e665037_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,931 Underlying: Common Stock · 202,500 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 21:30 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 1,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-001528 · e664940_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Stock · 138,200 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| October 01, 2025 Filed Oct 6, 2025 20:05 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 1,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-001409 · e664883_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,524 Underlying: Common Stock · 151,700 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:14 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 1,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-001252 · e664816_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,007 Underlying: Common Stock · 150,600 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 21:28 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-001159 · e664765_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,501 Underlying: Common Stock · 130,700 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:09 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-000978 · e664676_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,194 Underlying: Common Stock · 84,700 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:05 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-000773 · e664583_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,347 Underlying: Common Stock · 71,300 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| May 01, 2025 Filed May 23, 2025 21:42 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | OtherSeries D Convertible Preferred Stock · Derivative | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-25-000716 · e664546_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,634 Underlying: Common Stock · 69,400 shares Expires not disclosed F1 · derivative.exercise_price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · kind: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F1 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. F2 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| April 15, 2025 Filed May 6, 2025 01:13 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | GrantSeries D Convertible Preferred Stock · Derivative | 501 | $9.99 | $5,004.99 |
DisclosureSEC source: 0001193805-25-000608 · e664474_4-bdpt.xml · derivative · entry 5 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,940 Underlying: Common Stock · 50,100 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F6 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services based on a closing price per share of the Issuer's common stock of $0.0999 on April 15, 2025, times 100. F1 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| April 09, 2025 Filed May 6, 2025 01:13 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | PurchaseOption to Purchase Common Stock · Derivative | 1 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001193805-25-000608 · e664474_4-bdpt.xml · derivative · entry 4 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 500,000 shares Expires 2035-04-09 F5 · price: The option to purchase 500,000 shares of the Issuer's common stock was granted to the Reporting Person in connection with the Preferred D Stock Purchase Agreement, dated April 9, 2025, between the Issuer and the Reporting Person. No additional consideration was paid to the Issuer in exchange for such option beyond the consideration paid in exchange for the Series D Convertible Preferred Stock. Read SEC document |
| April 09, 2025 Filed May 6, 2025 01:13 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | PurchaseSeries D Convertible Preferred Stock · Derivative | 39,868 | $7.52 | $299,807.36 |
DisclosureSEC source: 0001193805-25-000608 · e664474_4-bdpt.xml · derivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,439 Underlying: Common Stock · 3,986,800 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F4 · price: The price per share is based on the average closing price of the Issuer's common stock for the five days prior to the transaction date, less a 20% discount, times 100. F1 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| March 15, 2025 Filed May 6, 2025 01:13 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | GrantSeries D Convertible Preferred Stock · Derivative | 479 | $10.45 | $5,005.55 |
DisclosureSEC source: 0001193805-25-000608 · e664474_4-bdpt.xml · derivative · entry 2 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,571 Underlying: Common Stock · 47,900 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F3 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services based on a closing price per share of the Issuer's common stock of $0.1045 on March 14, 2025, times 100. F1 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| February 15, 2025 Filed May 6, 2025 01:13 UTC | BIOADAPTIVES, INC. BDPT · Entity 1574 | GrantSeries D Convertible Preferred Stock · Derivative | 455 | $11.00 | $5,005.00 |
DisclosureSEC source: 0001193805-25-000608 · e664474_4-bdpt.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,092 Underlying: Common Stock · 45,500 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F2 · price: Represents shares of Series D Convertible Preferred Stock issued as compensation for board services based on a closing price per share of the Issuer's common stock of $0.1100 on February 14, 2025, times 100. F1 · derivative.exercise_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. F1 · derivative.expiration_date: The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 10% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 21:58 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 42,508 | $8.83 | $375,345.64 |
DisclosureSEC source: 0000899243-19-010087 · doc4.xml · nonDerivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,043,009 F3 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded RSU's that vested on 4/2/2019. F1 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 21:58 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 40,383 | $8.83 | $356,581.89 |
DisclosureSEC source: 0000899243-19-010087 · doc4.xml · nonDerivative · entry 2 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,085,517 F2 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded PSU's that vested on 4/2/2019. F1 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 21:46 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantCommon Stock | 401,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000858339-19-000093 · wf-form4_155416957266044.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023,276 F1 · shares: Represents Restricted Stock Units granted on March 28, 2019 which will vest and be prorated in accordance with the terms of the amendment, dated December 21, 2018, to the Separation Agreement dated November 1, 2018 between the reporting person and the Issuer. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 20:09 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 53,660 | $8.67 | $465,232.20 |
DisclosureSEC source: 0000858339-19-000062 · wf-form4_155364536007418.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621,439 F1 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 03/23/2019. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 14:51 UTC | Aptiv PLC APTV · Entity 3559 | GrantDividend Equivalent Right · Derivative | 5.31 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012382 · doc4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20.363 Underlying: Ordinary Shares · 5.31 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 20:25 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 12,132 | $9.22 | $111,857.04 |
DisclosureSEC source: 0000858339-19-000005 · wf-form4_154950272158797.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,712,967 F1 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 2/4/2019. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 20:37 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $9.45 | Not disclosed |
DisclosureSEC source: 0000858339-19-000003 · wf-form4_154907144172018.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 150,000 shares Expires 2025-02-05 F1 · shares: On February 5, 2015, the reporting person was awarded performance-based options to purchase 200,000 shares of common stock at a 5% EBITDA performance target and 200,000 shares of common stock at a 7.5% EDITDA performance target. Each option vests in four equal installments based on the Registrant's satisfaction of the performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017, and 2018. The performance options are eligible to vest based on a catch-up provision. The performance criteria in 2017 and 2018 for both targets were met, and approved for vesting as of February 4, 2019, resulting in vesting of 50,000 shares at 5% EBITDA performance and 100,000 shares at 7.5% EBITDA performance for a total of 150,000 shares. F1 · price: On February 5, 2015, the reporting person was awarded performance-based options to purchase 200,000 shares of common stock at a 5% EBITDA performance target and 200,000 shares of common stock at a 7.5% EDITDA performance target. Each option vests in four equal installments based on the Registrant's satisfaction of the performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017, and 2018. The performance options are eligible to vest based on a catch-up provision. The performance criteria in 2017 and 2018 for both targets were met, and approved for vesting as of February 4, 2019, resulting in vesting of 50,000 shares at 5% EBITDA performance and 100,000 shares at 7.5% EBITDA performance for a total of 150,000 shares. F2 · derivative.exercise_date: Options are exercisable as of February 4, 2019. Read SEC document |
| January 30, 2019 Filed Apr 4, 2019 21:58 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantCommon Stock | 102,624 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-010087 · doc4.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125,900 F1 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| November 21, 2018 Filed Nov 26, 2018 19:01 UTC | Aptiv PLC APTV · Entity 3559 | GrantDividend Equivalent Right · Derivative | 5.902 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-059896 · doc4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15.053 Underlying: Ordinary Shares · 5.902 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| October 06, 2018 Filed Oct 10, 2018 19:38 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 126,812 | $9.70 | $1,230,076.40 |
DisclosureSEC source: 0000858339-18-000256 · wf-form4_153921467673236.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,552 F1 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 10/06/2018. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 16:33 UTC | Aptiv PLC APTV · Entity 3559 | GrantDividend Equivalent Right · Derivative | 4.752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-048312 · doc4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9.151 Underlying: Ordinary Shares · 4.752 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 13:47 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | PurchaseCommon Stock | 100,000 | $9.55 | $954,820.00 |
DisclosureSEC source: 0000858339-18-000221 · wf-form4_153357765228269.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047,364 F1 · price: The price reported in Column 4 is an weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.525 to $9.55 inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 16:45 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 58,184 | $10.70 | $622,568.80 |
DisclosureSEC source: 0000858339-18-000204 · wf-form4_153065068902559.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037,042 F1 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 06/29/2018. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 17:08 UTC | Aptiv PLC APTV · Entity 3559 | SaleOrdinary Shares | 7,826 | $102.59 | $802,837.25 |
DisclosureSEC source: 0001209191-18-038245 · doc4.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Mark P Frissora Revocable Trust Disclosed balance after: 3,902 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $102.55 to $102.63, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 23, 2018 Filed May 25, 2018 12:49 UTC | Aptiv PLC APTV · Entity 3559 | GrantDividend Equivalent Right · Derivative | 4.399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033308 · doc4.xml · derivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4.399 Underlying: Ordinary Shares · 4.399 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| May 14, 2018 Filed May 25, 2018 12:49 UTC | Aptiv PLC APTV · Entity 3559 | GiftOrdinary Shares | 2,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033308 · doc4.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,957 Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 16:54 UTC | Aptiv PLC APTV · Entity 3559 | GrantOrdinary Shares | 1,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-026406 · doc4.xml · nonDerivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,214 F4 · price: The Reporting Person has received restricted stock units that each represent a right to receive one ordinary share of the Issuer pursuant to the Issuer's Long Term Incentive Plan, as amended and restated, and will vest in full one day before the Issuer's Annual Meeting of Shareholders in 2019. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 16:54 UTC | Aptiv PLC APTV · Entity 3559 | OtherDividend Equivalent Right · Derivative | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-026406 · doc4.xml · derivative · entry 5 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31 shares Expires not disclosed F1 · derivative.exercise_price: Settlement of dividend equivalent rights in connection with the vesting of restricted stock units. The rights accrued when and as dividends were paid on the Issuer's ordinary shares and vest upon the vesting of the restricted stock unit to which they relate. Each dividend equivalent right is the economic equivalent of one ordinary share. F5 · shares: Reflects here and in Table 1 above the Spin-Off Adjustment to the Reporting Person's dividend equivalent rights. F1 · derivative.exercise_date: Settlement of dividend equivalent rights in connection with the vesting of restricted stock units. The rights accrued when and as dividends were paid on the Issuer's ordinary shares and vest upon the vesting of the restricted stock unit to which they relate. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: Settlement of dividend equivalent rights in connection with the vesting of restricted stock units. The rights accrued when and as dividends were paid on the Issuer's ordinary shares and vest upon the vesting of the restricted stock unit to which they relate. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 16:54 UTC | Aptiv PLC APTV · Entity 3559 | Tax withholdingOrdinary Shares | 284 | $85.21 | $24,199.64 |
DisclosureSEC source: 0001209191-18-026406 · doc4.xml · nonDerivative · entry 2 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,257 F3 · price: Shares withheld to pay current tax liabilities incident to the vesting of restricted stock units and settlement of dividend equivalent rights. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 16:54 UTC | Aptiv PLC APTV · Entity 3559 | OtherOrdinary Shares | 31 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-026406 · doc4.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,541 F1 · price: Settlement of dividend equivalent rights in connection with the vesting of restricted stock units. The rights accrued when and as dividends were paid on the Issuer's ordinary shares and vest upon the vesting of the restricted stock unit to which they relate. Each dividend equivalent right is the economic equivalent of one ordinary share. F2 · balance_after: Reflects an antidilution adjustment (the "Spin-Off Adjustment") to the number of ordinary shares reported held by the Reporting Person, which Spin-Off Adjustment was made prior to this vesting date in connection with the spin-off of Delphi Technologies PLC from the Issuer on December 4, 2017. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 21:37 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantCommon Stock | 324,075 | $0.00 | $0.00 |
DisclosureSEC source: 0000858339-18-000144 · wf-form4_152289223308177.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,177,930 F1 · shares: Represents Restricted Stock Units ("RSUs") granted on April 2, 2018 and which vest in one-third equal annual installments on each of April 2, 2019, April 2, 2020, and April 2, 2021. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:11 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 53,660 | $11.25 | $603,675.00 |
DisclosureSEC source: 0000858339-18-000085 · wf-form4_152219949844578.xml · nonDerivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,853,855 F1 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 03/23/2018. F2 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 20:22 UTC | Aptiv PLC APTV · Entity 3559 | GrantDividend Equivalent Right · Derivative | 6.015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-010779 · doc4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30.015 Underlying: Ordinary Shares · 6.015 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F2 · balance_after: Reflects an antidilution adjustment to the number of dividend equivalent rights held by the Reporting Person, which antidilution adjustment was made prior to the payment of these dividend equivalent rights, in connection with the spin-off of Delphi Technologies PLC from the Issuer on December 4, 2017. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 20:54 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantEmployee stock option (right to buy) · Derivative | 50,000 | $9.45 Strike: $9.45 | $472,500.00 |
DisclosureSEC source: 0000858339-18-000024 · wf-form4_151805483638869.xml · derivative · entry 4 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2025-02-05 F5 · shares: On February 5, 2015, the reporting person was awarded performance-based options to purchase 200,000 shares of common stock at a 5% EBITDA performance target. The option vests in four equal installments based on the Registrant's satisfaction of the performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017, and 2018. The performance criteria in 2017 for the 5% target was met and approved for vesting as of February 5, 2018 of a total of 50,000 shares . F6 · derivative.exercise_date: Options are exercisable as of February 5, 2018. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 20:54 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | Tax withholdingCommon Stock | 12,145 | $13.25 | $160,921.25 |
DisclosureSEC source: 0000858339-18-000024 · wf-form4_151805483638869.xml · nonDerivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945,370 F3 · shares: Withholding of shares by the Company for tax withholding purposes related to the vesting of previously awarded Restricted Stock Units that vested on 02/05/2018. F4 · balance_after: Includes shares of Common Stock beneficially owned and unvested RSUs previously granted and reported. Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 18:43 UTC | Aptiv PLC DLPH · Entity 3559 | GrantDividend Equivalent Right · Derivative | 6.195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-062529 · doc4.xml · derivative · entry 1 FRISSORA MARK P · CIK 0001239786 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19.973 Underlying: Ordinary Shares · 6.195 shares Expires not disclosed F1 · derivative.exercise_price: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.exercise_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. F1 · derivative.expiration_date: The dividend equivalent rights accrued with respect to an outstanding award of restricted stock units. Each dividend equivalent right is the economic equivalent of one ordinary share. Read SEC document |
| October 06, 2017 Filed Oct 11, 2017 17:18 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantCommon Stock | 147,862 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-024032 · doc4.xml · nonDerivative · entry 3 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,070 F1 · security: Shares of Class A common stock, par value $0.001 per share ("CAC Common Stock"), of the corporation then known as Caesars Acquisition Company ("CAC") were converted into shares of common stock, par value $0.01 per share, of the Issuer ("CEC Common Stock") pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated as of July 9, 2016, between the Issuer and CAC, as amended by the First Amendment to Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2017 (as amended, the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of CAC Common Stock was exchanged for 1.625 shares of CEC Common Stock. F5 · shares: The reporting person held 90,992 shares of CAC Common Stock in Restricted Stock in a trust prior to the conversion pursuant to the Merger Agreement. F6 · balance_after: Represents shares held in a trust. Read SEC document |
| October 06, 2017 Filed Oct 11, 2017 17:18 UTC | CAESARS HOLDINGS, INC. CZR · Entity 11848 | GrantCommon Stock | 1,289,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-024032 · doc4.xml · nonDerivative · entry 2 FRISSORA MARK P · CIK 0001239786 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,957,515 F4 · shares: Represents the grant of Restricted Stock Units, each of which represent the contingent right to receive one share of CEC Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.